S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Stock market today: Global markets are mixed as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
TKO Group Knocks Out WrestleMania Event Record
Novo Nordisk Arms Wegovy to Be a Triple Threat
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Stock market today: Global markets are mixed as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
TKO Group Knocks Out WrestleMania Event Record
Novo Nordisk Arms Wegovy to Be a Triple Threat
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Stock market today: Global markets are mixed as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
TKO Group Knocks Out WrestleMania Event Record
Novo Nordisk Arms Wegovy to Be a Triple Threat
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Stock market today: Global markets are mixed as Middle East tensions escalate
Citi’s Results Say This About The Stock Market
TKO Group Knocks Out WrestleMania Event Record
Novo Nordisk Arms Wegovy to Be a Triple Threat
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
NASDAQ:MRNA

Moderna (MRNA) Stock Price, News & Analysis

$105.14
-1.87 (-1.75%)
(As of 04/12/2024 08:52 PM ET)
Today's Range
$104.65
$107.88
50-Day Range
$85.37
$111.98
52-Week Range
$62.55
$163.24
Volume
2.42 million shs
Average Volume
4.30 million shs
Market Capitalization
$40.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$126.49

Moderna MarketRank™ Stock Analysis

Analyst Rating
Hold
2.24 Rating Score
Upside/​Downside
20.3% Upside
$126.49 Price Target
Short Interest
Bearish
6.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.21mentions of Moderna in the last 14 days
Based on 45 Articles This Week
Insider Trading
Selling Shares
$9.97 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.48) to ($5.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.04 out of 5 stars

Medical Sector

182nd out of 927 stocks

Biological Products, Except Diagnostic Industry

20th out of 154 stocks

MRNA stock logo

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Stock Price History

MRNA Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Moderna Betrays Africa, Says AHF
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Moderna: Considering The Cancer Vaccine Angle
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/14/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MRNA
Fax
N/A
Employees
5,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$126.49
High Stock Price Target
$231.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+20.3%
Consensus Rating
Hold
Rating Score (0-4)
2.24
Research Coverage
17 Analysts

Profitability

Net Income
$-4,714,000,000.00
Pretax Margin
-57.56%

Debt

Sales & Book Value

Annual Sales
$6.85 billion
Book Value
$36.33 per share

Miscellaneous

Free Float
322,768,000
Market Cap
$40.26 billion
Optionable
Optionable
Beta
1.62

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Moderna, Inc.:

  • Moderna, Inc. is a biotechnology company that focuses on developing messenger RNA therapeutics and vaccines for various diseases, including COVID-19.
  • The company has a strong pipeline of vaccines targeting infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases.
  • Moderna has strategic alliances and collaborations with major pharmaceutical companies like AstraZeneca and Merck & Co., Inc., which can enhance its research and development capabilities.
  • Recent positive clinical trial results and regulatory approvals have boosted investor confidence in Moderna's products and potential market growth.
  • Despite fluctuations, Moderna's stock price has shown resilience and potential for growth, making it an attractive investment option in the biotechnology sector.

Cons

Investors should be bearish about investing in Moderna, Inc. for these reasons:

  • Biotechnology investments can be volatile due to regulatory uncertainties, clinical trial outcomes, and competitive pressures, which may pose risks to investor returns.
  • Moderna's success heavily relies on the continued efficacy and safety of its mRNA-based vaccines, and any setbacks in this technology could impact the company's future prospects.
  • The biotechnology industry is highly competitive, with rapid advancements and innovations, leading to potential challenges for Moderna to maintain its market position and profitability.
  • Investing in biotechnology companies like Moderna requires a high tolerance for risk and a long-term investment horizon, as returns may not materialize immediately and could be subject to market fluctuations.
  • Market conditions, regulatory changes, and global health crises can significantly influence the demand for Moderna's products, affecting the company's financial performance and stock valuation.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 9, 2024. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

MRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings
or view top-rated stocks.

What is Moderna's stock price target for 2024?

17 analysts have issued twelve-month price objectives for Moderna's stock. Their MRNA share price targets range from $60.00 to $231.00. On average, they predict the company's stock price to reach $126.49 in the next year. This suggests a possible upside of 20.3% from the stock's current price.
View analysts price targets for MRNA
or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2024?

Moderna's stock was trading at $99.45 at the beginning of 2024. Since then, MRNA stock has increased by 5.7% and is now trading at $105.14.
View the best growth stocks for 2024 here
.

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MRNA earnings forecast
.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings data on Thursday, February, 22nd. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to analysts' expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative trailing twelve-month return on equity of 10.23%. The firm's revenue for the quarter was down 44.9% compared to the same quarter last year. During the same period last year, the business earned $3.61 EPS.

What guidance has Moderna issued on next quarter's earnings?

Moderna updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

Moderna (MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.10%), Czech National Bank (0.02%), Banque Cantonale Vaudoise (0.01%), Gulf International Bank UK Ltd (0.01%), Los Angeles Capital Management LLC (0.01%) and Richard P Slaughter Associates Inc (0.01%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends
.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNA) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners